The evolving role of 131I for the treatment of differentiated thyroid carcinoma

Richard J. Robbins, Martin J. Schlumberger

Research output: Contribution to journalArticlepeer-review

175 Scopus citations


The use of radioactive iodine (131I) for the treatment of thyroid carcinoma has changed over the past 50 y. These changes are based on increasing awareness of the biophysical properties of 131I and new discoveries concerning the biology of iodine handling by thyroid cells. The therapeutic administration of 131I for thyroid remnant ablation and for metastases requires an appreciation of iodine clearance kinetics, of factors that can alter the occupancy time of 131I within lesions, and of the role of thyroid-stimulating hormone in stimulating the sodium-iodide symporter. The potential complications and adverse events associated with 131I are discussed. 131I will continue to be a major weapon in the fight against metastatic thyroid carcinoma. Its future role will be modified by expanding knowledge of its relative risks and benefits.

Original languageEnglish (US)
Pages (from-to)28S-37S
JournalJournal of Nuclear Medicine
Issue number1 SUPPL.
StatePublished - Jan 1 2005


  • Adverse effects
  • Carcinogenesis
  • Dosimetry
  • Metastases
  • Radioactive iodine
  • Thyroid carcinoma

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology


Dive into the research topics of 'The evolving role of 131I for the treatment of differentiated thyroid carcinoma'. Together they form a unique fingerprint.

Cite this